Leerink Swann Starts Trius Therapeutics (TSRX) at Outperform, Sees a More than Double
Tweet Send to a FriendGet Alerts TSRX Hot Sheet
Price: $7.95 +0.63%
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade TSRX Now!
Leerink Swann initiates coverage on Trius Therapeutics (NASDAQ: TSRX) with a Outperform. PT $10.00.
The firm comments, "Lead drug candidate Tedizolid (TZD) is increasingly differentiated from PFE’s (MP) market leader Linezolid (LZD), which should allow TSRX to successfully launch and maintain premium pricing for TZD even after LZD becomes generic in 2015. MEDACorp KOLs believe TZD’s key differentiation from LZD relates to: (1) improved hematologic profile (less myelosuppression);
(2) lack of drug-drug-interactions (DDI), and (3) an improved resistance profile. Our base case valuation assumes TZD maintains premium pricing and conservatively leads to our $10 DCF valuation. A worst case scenario (not our valuation) assumes TZD is priced in line with generic LZD and leads to a ~$4.50 estimate, which provides minimal downside from current levels."
For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.
Shares of Trius Therapeutics closed at $4.91 yesterday, with a 52 week range of $4.66-$8.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "Lead drug candidate Tedizolid (TZD) is increasingly differentiated from PFE’s (MP) market leader Linezolid (LZD), which should allow TSRX to successfully launch and maintain premium pricing for TZD even after LZD becomes generic in 2015. MEDACorp KOLs believe TZD’s key differentiation from LZD relates to: (1) improved hematologic profile (less myelosuppression);
(2) lack of drug-drug-interactions (DDI), and (3) an improved resistance profile. Our base case valuation assumes TZD maintains premium pricing and conservatively leads to our $10 DCF valuation. A worst case scenario (not our valuation) assumes TZD is priced in line with generic LZD and leads to a ~$4.50 estimate, which provides minimal downside from current levels."
For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.
Shares of Trius Therapeutics closed at $4.91 yesterday, with a 52 week range of $4.66-$8.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Guggenheim Starts Biota Pharmaceuticals (BOTA) at Buy
- Topeka Capital Starts InvenSense (INVN) at Buy
- Roth Capital Resumes Kid Brands (KID) at Neutral
Create E-mail Alert Related Categories
Hot New Coverage, New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
